LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 14

Search options

  1. Article ; Online: Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study.

    Chavez-Tapia, Norberto Carlos / Sanchez-Jimenez, Beatriz A / Vidaña-Perez, Desiree / Corrales-Rosas, Beatriz / Balderas-Garces, Brenda / Vera-Izaguirre, Diana / Santa Cruz, Fermin Jurado / Maldonado-Garcia, Cesar / Juarez-Hernandez, Eva / Uribe, Misael

    PloS one

    2024  Volume 19, Issue 4, Page(s) e0290632

    Abstract: Psoriasis has been related to metabolic dysfunction-associated fatty liver disease and, liver fibrosis. This study aimed to evaluate the prevalence of liver fibrosis in psoriasis and identify predictors for fibrosis. This is a cross-sectional study ... ...

    Abstract Psoriasis has been related to metabolic dysfunction-associated fatty liver disease and, liver fibrosis. This study aimed to evaluate the prevalence of liver fibrosis in psoriasis and identify predictors for fibrosis. This is a cross-sectional study conducted from December 2012 to June 2016 assessing psoriasis and psoriatic arthritis patients attended at four centers in Mexico City. Data regarding history of the skin disease, previous and current medication, and previously diagnosed liver disease was collected. Liver fibrosis was assessed with four different non-invasive methods (FIB4, APRI, NAFLD score and elastography). We compared data based on the presence of fibrosis. Adjusted-logistic regression models were performed to estimate OR and 95% CI. A total of 160 patients were included. The prevalence of significant fibrosis using elastography was 25% (n = 40), and 7.5% (n = 12) for advanced fibrosis. Patients with fibrosis had higher prevalence of obesity (60% vs 30.8%, P = 0.04), type 2 diabetes (40% vs 27.5%, P = 0.003), gamma-glutamyl transpeptidase levels (70.8±84.4 vs. 40.1±39.2, P = 0.002), and lower platelets (210.7±58.9 vs. 242.8±49.7, P = 0.0009). Multivariate analysis showed that body mass index (OR1.11, 95%CI 1.02-1.21), type 2 diabetes (OR 3.44, 95%CI 1.2-9.88), and gamma-glutamyl transpeptidase (OR 1.01, 95%CI1-1.02) were associated with the presence of fibrosis. The use of methotrexate was not associated. Patients with psoriasis are at higher risk of fibrosis. Metabolic dysfunction, rather than solely the use of hepatotoxic drugs, likely plays a major role; it may be beneficial to consider elastography regardless of the treatment used. Metabolic factors should be assessed, and lifestyle modification should be encouraged.
    MeSH term(s) Humans ; Cross-Sectional Studies ; Diabetes Mellitus, Type 2/complications ; gamma-Glutamyltransferase ; Liver Cirrhosis/complications ; Liver Cirrhosis/epidemiology ; Liver Cirrhosis/diagnosis ; Non-alcoholic Fatty Liver Disease/complications ; Non-alcoholic Fatty Liver Disease/epidemiology ; Non-alcoholic Fatty Liver Disease/diagnosis ; Psoriasis/complications ; Psoriasis/epidemiology ; Fibrosis ; Elasticity Imaging Techniques/methods
    Chemical Substances gamma-Glutamyltransferase (EC 2.3.2.2)
    Language English
    Publishing date 2024-04-16
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 2267670-3
    ISSN 1932-6203 ; 1932-6203
    ISSN (online) 1932-6203
    ISSN 1932-6203
    DOI 10.1371/journal.pone.0290632
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Abordaje diagnóstico de la eritrodermia en el adulto.

    Maldonado-García, César Alfonso / Orozco-Anahuati, Ana Paula

    Revista medica del Instituto Mexicano del Seguro Social

    2017  Volume 55, Issue 3, Page(s) 353–360

    Abstract: Erythroderma consists on erythema and scaling that covers more than 90% of the cutaneous surface. It has multiple causes and for the most common we can use the acronym PALM (psoriasis, atopic dermatitis, lymphoproliferative disease and medication). It is ...

    Title translation Diagnostic approach of erythroderma in the adult.
    Abstract Erythroderma consists on erythema and scaling that covers more than 90% of the cutaneous surface. It has multiple causes and for the most common we can use the acronym PALM (psoriasis, atopic dermatitis, lymphoproliferative disease and medication). It is important to diagnose the cause in order to get a prognosis and a targeted treatment. In 30% of the cases the cause is not evident and the patient requires periodic assessment to rule out evolution to a lymphoproliferative disease. In many cases, erythroderma is a chronic disease but it can also be a life-threatening dermatologic urgency that requires hospitalization.
    Language Spanish
    Publishing date 2017-05
    Publishing country Mexico
    Document type English Abstract ; Journal Article
    ZDB-ID 732133-8
    ISSN 0443-5117 ; 0484-7849
    ISSN 0443-5117 ; 0484-7849
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Biosimilar medicines for psoriasis. Positioning of the Mexican Academy of Dermatology.

    García-Hidalgo, Linda / Méndez-Flores, Silvia / Carrillo-Vázquez, Sandra / Estrada-Aguilar, Lorena / García-Salazar, Ma Del Rosario / Gómez-Flores, Minerva / López-Tello, Adriana / Charli-Joseph, Yann / Maldonado-García, César / Serrano-Jaén, Liliana

    Gaceta medica de Mexico

    2020  Volume 156, Issue Supl, Page(s) 1–14

    Abstract: The development and marketing of biosimilars opens a new scenario in the treatment of many pathologies, including psoriasis. This article reflects the position of the Mexican Academy of Dermatology (AMD) on the use of biosimilar medicines for the ... ...

    Title translation Medicamentos biocomparables para la psoriasis. Posicionamiento de la Academia Mexicana de Dermatología.
    Abstract The development and marketing of biosimilars opens a new scenario in the treatment of many pathologies, including psoriasis. This article reflects the position of the Mexican Academy of Dermatology (AMD) on the use of biosimilar medicines for the treatment of psoriasis in Mexico. In summary, the AMD estates that there is sufficient evidence to accept comparability of pharmacokinetics and pharmacodynamics of some biosimilar medicines to adalimumab, infliximab and etanercept; this evidence does not sufficiently support interchangeability or indication extrapolation. It is essential to establish a close pharmacovigilance not only to guarantee compliance with the Cofepris rules in Mexico, but also to facilitate the effective monitoring of the adverse effects of biosimilar medicines. Although the goal of biotechnological drugs is to achieve substantial savings for patients and public institutions, no economic criteria should prevail over rigorous scientific criteria that guarantee maximum therapeutic efficacy and optimum safety for patients.
    MeSH term(s) Adalimumab/administration & dosage ; Adalimumab/adverse effects ; Biosimilar Pharmaceuticals/administration & dosage ; Biosimilar Pharmaceuticals/adverse effects ; Biosimilar Pharmaceuticals/therapeutic use ; Dermatologic Agents/administration & dosage ; Dermatologic Agents/adverse effects ; Dermatologic Agents/pharmacokinetics ; Dermatology ; Drug Approval ; Etanercept/administration & dosage ; Etanercept/adverse effects ; Humans ; Infliximab/administration & dosage ; Infliximab/adverse effects ; Mexico ; Pharmacovigilance ; Psoriasis/drug therapy
    Chemical Substances Biosimilar Pharmaceuticals ; Dermatologic Agents ; Infliximab (B72HH48FLU) ; Adalimumab (FYS6T7F842) ; Etanercept (OP401G7OJC)
    Language English
    Publishing date 2020-06-01
    Publishing country Mexico
    Document type Journal Article
    ZDB-ID 425456-9
    ISSN 0016-3813
    ISSN 0016-3813
    DOI 10.24875/GMM.M20000347
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients.

    Aguilar-Flores, Cristina / Castro-Escamilla, Octavio / Ortega-Rocha, Elizabeth M / Maldonado-García, César / Jurado-Santa Cruz, Fermín / Pérez-Montesinos, Gibrán / Lemini-López, Alicia / Bonifaz, Laura C

    Mediators of inflammation

    2020  Volume 2020, Page(s) 8065147

    Abstract: Psoriasis is an inflammatory autoimmune disease characterized by cutaneous lesions in plaques. It has been proposed that the immune response has a key role in the disease progression. Particularly, the Th17 cells through IL-17 can contribute to maintain ... ...

    Abstract Psoriasis is an inflammatory autoimmune disease characterized by cutaneous lesions in plaques. It has been proposed that the immune response has a key role in the disease progression. Particularly, the Th17 cells through IL-17 can contribute to maintain the inflammatory process. The pathogenic Th17 phenotype has been described in human diseases and associated with high severity in inflammatory experimental models. However, it is not clear if the pathogenic phenotype could be present in the skin and peripheral blood as well as its possible association to severity in psoriasis. In the lesional skin, we found high infiltration of Th17 cells and the pathogenic phenotype, finding a correlation between the frequency of Th17 cells and the Psoriasis Area and Severity Index (PASI) score. In peripheral blood, we observed a pool of Th17 lymphocytes with potential to acquire pathogenic features. Interestingly, the percentage of pathogenic Th17 cells (CD4
    MeSH term(s) Flow Cytometry ; Fluorescent Antibody Technique ; Humans ; Microscopy, Confocal ; Psoriasis/blood ; Psoriasis/genetics ; Psoriasis/metabolism ; Skin/metabolism ; Th17 Cells/metabolism ; Tumor Necrosis Factor-alpha/blood
    Chemical Substances Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2020-07-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1137605-3
    ISSN 1466-1861 ; 0962-9351
    ISSN (online) 1466-1861
    ISSN 0962-9351
    DOI 10.1155/2020/8065147
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Necrotic carpal tunnel syndrome in a child.

    Maldonado García, César / Valente Duarte de Sousa, Isabel Cristina / López Cepeda, Larissa

    Pediatric dermatology

    2014  Volume 31, Issue 4, Page(s) 500–503

    Abstract: Median nerve entrapment at the wrist level causes carpal tunnel syndrome (CTS). Although frequent in adults, CTS is a rare entity in children. Bouvier described an exceptional necrotic variant in 1979 in which skin, nail, and bone lesions are typical. We ...

    Abstract Median nerve entrapment at the wrist level causes carpal tunnel syndrome (CTS). Although frequent in adults, CTS is a rare entity in children. Bouvier described an exceptional necrotic variant in 1979 in which skin, nail, and bone lesions are typical. We report the case of a 10-year-old child with necrotic CTS secondary to trauma. To our knowledge, this is the first case reported in a child.
    MeSH term(s) Carpal Tunnel Syndrome/diagnosis ; Carpal Tunnel Syndrome/etiology ; Carpal Tunnel Syndrome/surgery ; Child ; Decompression, Surgical ; Humans ; Male ; Necrosis ; Wounds and Injuries/complications
    Language English
    Publishing date 2014-07
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 605539-4
    ISSN 1525-1470 ; 0736-8046
    ISSN (online) 1525-1470
    ISSN 0736-8046
    DOI 10.1111/pde.12066
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Expert recommendations for biological treatment in patients with psoriasis.

    Podoswa-Ozerkovsky, Nancy / Amaya-Guerra, Mario / Barba-Gómez, José F / Estrada-Aguilar, Lorena / Gómez-Flores, Minerva / Lopeztello-Santillan, Adriana L / Maldonado-García, César A / Rivera-Gómez, Mónica I / Villanueva-Quintero, Delfina G / León-Dorantes, Gladys

    Gaceta medica de Mexico

    2020  Volume 156, Issue 5, Page(s) 446–453

    Abstract: In recent years, the introduction of a series of biological drugs for the treatment of psoriasis has considerably increased the therapeutic armamentarium of doctors, and thus a strongly positive impact on the control of this condition has been achieved. ... ...

    Title translation Recomendaciones de expertos para el tratamiento biológico en pacientes con psoriasis.
    Abstract In recent years, the introduction of a series of biological drugs for the treatment of psoriasis has considerably increased the therapeutic armamentarium of doctors, and thus a strongly positive impact on the control of this condition has been achieved. With the purpose to provide the best recommendations for the use of these biological agents in patients with psoriasis, the Mexican group of psoriasis experts, PSOMEX, has developed recommendations in order to improve the understanding and therapeutic positioning of this type of medications.
    MeSH term(s) Age Factors ; Biological Factors/therapeutic use ; Female ; Humans ; Male ; Mexico ; Pregnancy ; Pregnancy Complications/therapy ; Psoriasis/therapy ; Societies, Medical ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
    Chemical Substances Biological Factors ; TNF protein, human ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2020-12-23
    Publishing country Mexico
    Document type Journal Article ; Practice Guideline ; Review
    ZDB-ID 425456-9
    ISSN 0016-3813
    ISSN 0016-3813
    DOI 10.24875/GMM.M20000441
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.

    Adsit, Sandra / Zaldivar, Enrique Rivas / Sofen, Howard / Dei-Cas, Ignacio / Maldonado-García, César / Peñaranda, Elkin O / Puig, Luís / Meng, Xiangyi / Fox, Todd / Guana, Adriana

    Advances in therapy

    2017  Volume 34, Issue 6, Page(s) 1327–1339

    Abstract: Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was ... ...

    Abstract Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients.
    Methods: Data were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup.
    Results: Efficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator's Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52.
    Conclusions: Secukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients.
    Funding: Novartis Pharmaceutical Corporation.
    MeSH term(s) Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Double-Blind Method ; Etanercept/therapeutic use ; Female ; Hispanic Americans ; Humans ; Male ; Psoriasis/drug therapy ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; secukinumab (DLG4EML025) ; Etanercept (OP401G7OJC)
    Language English
    Publishing date 2017-04-10
    Publishing country United States
    Document type Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-017-0521-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.

    Adsit, Sandra / Zaldivar, Enrique Rivas / Sofen, Howard / Dei-Cas, Ignacio / Maldonado-García, César / Peñaranda, Elkin O / Puig, Luís / Meng, Xiangyi / Fox, Todd / Guana, Adriana

    Advances in therapy

    2017  Volume 34, Issue 7, Page(s) 1772

    Language English
    Publishing date 2017
    Publishing country United States
    Document type Journal Article ; Published Erratum
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-017-0563-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Metas mexicanas de tratamiento de psoriasis en placas.

    Estrada-Aguilar, Lorena / Amaya-Guerra, Mario / Gómez-Flores, Minerva / Guevara-Sanginés, Esther / Jurado-Santacruz, Fermín / Lopeztello-Santillán, Adriana / Maldonado-García, César / Rivera-Gómez, Mónica / Rodríguez-Martínez, Norma / Vega-González, Luis

    Revista medica del Instituto Mexicano del Seguro Social

    2017  Volume 55, Issue 1, Page(s) 90–97

    Abstract: Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will ... ...

    Title translation Mexican treatment goals for plaque psoriasis.
    Abstract Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease. The European group met to develop the definitions of severity of psoriasis, treatment goals for moderate to severe disease, and optimization options and / or therapeutic transition than a paper published in 2011 was obtained. In Mexico a working group of experts on biological therapy (GTEB), made up of 10 members and an extended group of 150 dermatologists' voters in the country for the purpose of issuing Mexico's position on the proposals of the European group was formed. In this document the findings of the Working Group of Experts on Biological Therapy in Mexico are listed.
    MeSH term(s) Aftercare ; Combined Modality Therapy ; Delphi Technique ; Dermatologic Agents/therapeutic use ; Goals ; Humans ; Mexico ; Phototherapy ; Psoriasis/diagnosis ; Psoriasis/therapy ; Severity of Illness Index
    Chemical Substances Dermatologic Agents
    Language Spanish
    Publishing date 2017-01
    Publishing country Mexico
    Document type Consensus Development Conference ; Journal Article ; Practice Guideline
    ZDB-ID 732133-8
    ISSN 0443-5117 ; 0484-7849
    ISSN 0443-5117 ; 0484-7849
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: SEB Stimulation Induces Functional Pathogenic Features in Th17 Cells from Psoriasis Patients.

    Castro-Escamilla, Octavio / Aguilar-Flores, Cristina / Mora-Velandia, Luz María / Morán-Martínez, Karina / Fernández-Madinaveitia, Diana Edith / Lemini-López, Alicia / González-Palacios, Elizabeth / Maldonado-García, César / Jurado-Santa Cruz, Fermín / Pérez-Montesinos, Gibrán / Bonifaz, Laura C

    The Journal of investigative dermatology

    2018  Volume 138, Issue 12, Page(s) 2677–2681

    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Cell Differentiation ; Cell Proliferation ; Cells, Cultured ; Cytokines/metabolism ; Enterotoxins/metabolism ; Female ; Humans ; Langerhans Cells/immunology ; Lymphocyte Activation ; Male ; Middle Aged ; Psoriasis/immunology ; Severity of Illness Index ; Skin/immunology ; Th17 Cells/immunology
    Chemical Substances Cytokines ; Enterotoxins ; enterotoxin B, staphylococcal (39424-53-8)
    Language English
    Publishing date 2018-06-08
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 80136-7
    ISSN 1523-1747 ; 0022-202X
    ISSN (online) 1523-1747
    ISSN 0022-202X
    DOI 10.1016/j.jid.2018.05.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top